Articles tagged with Vaccine Development
MIT researchers have developed a method to reveal the inner workings of protein language models, which can accurately predict proteins suitable for drug or vaccine targets. By analyzing sparse representations of proteins, they identified key features that drive these predictions.
Researchers used machine-learning models to design nanoparticles that can deliver RNA to cells more efficiently. The approach accelerated the identification of optimal ingredient mixtures in lipid nanoparticles, leading to better delivery vehicles for RNA vaccines and mRNA therapies. This could dramatically speed up the development of ...
A new report from the Microbiology Society argues that vaccine deployment can slow AMR emergence. The UK Government is called upon to remove barriers and incentivize public-private collaboration for vaccine development.
A novel cancer vaccine has shown encouraging early results in patients with pancreatic and colorectal cancer, two of the most difficult-to-treat malignancies. The vaccine targets KRAS mutations found in about 25% of solid tumors and drives about 90% of pancreatic cancers and 50% of colorectal cancers.
This book delves into the scientific foundations of mucosal vaccine platforms, discussing immunological mechanisms, novel adjuvants, and real-world development challenges. It serves as a valuable resource for professionals and students in life sciences, immunology, and pharmacology.
The TherVacB vaccine aims to activate the natural immune response to eliminate the hepatitis B virus. In a new phase 1b/2a clinical trial, 81 patients will receive increasing doses of the vaccine components to determine its safety and effectiveness.
Researchers at Scripps Research Institute have developed a new microchip that can reveal how antibodies interact with viruses, allowing for faster and clearer insights into vaccine development. The technology offers a quicker-than-ever method to analyze antibody interactions, enabling scientists to design more effective vaccines.
Renowned vaccine expert Pierre Van Damme shared his experience leading over 500 clinical trials and establishing Vaccinopolis, a global research hub for vaccine clinical trials. The Vaccine Innovation Center of Korea University's College of Medicine aims to expand global cooperation in vaccine R&D through special seminars.
Researchers at MIT and Scripps Research Institute developed a vaccine that generates many more HIV-targeting B cells in mice with just one dose, using two adjuvants. The dual-adjuvant vaccine produces a wider diversity of antibodies against an HIV antigen, allowing the immune system to build up a stronger response.
Researchers have discovered a way to enhance the effectiveness of mRNA vaccines by disguising them as virus-like particles, prompting a stronger immune response in mice. The innovation could lead to lower doses and longer-lasting immunity.
Researchers have identified a critical step in SARS-CoV-2 viral infection: the protective role of ORF3a, which forms dense bodies surrounding the spike protein to prevent it from being cut into smaller components. This finding could lead to new therapeutic targets and vaccine development strategies.
The clinical trial demonstrated that the vaccine was safe and fully attenuated, causing no malaria infections in adults. The vaccine has the potential to achieve unprecedented potency and is designed to align with WHO's goals for malaria elimination.
A new mRNA vaccine has shown to be more effective and less costly to develop, inducing a robust immune response against SARS-CoV-2 variants. The vaccine's trans-amplifying platform allows for reduced production costs and potential broad protection.
The European Vaccines Hub for Pandemic Readiness (EVH) is a pan-European center that integrates excellence in vaccine research, human monoclonal antibody development, clinical trials, and scalable manufacturing. EVH aims to drive innovation and ensure strategic autonomy in vaccine R&D and manufacturing.
A study found that adults hospitalized for RSV had significantly higher odds of cardiac events compared to those with COVID-19 or influenza. The findings suggest that preexisting cardiovascular risk patients should consider vaccination against respiratory viral infections.
Researchers from the University of Cincinnati have engineered bacteria to deliver antiviral therapies and vaccines orally, bypassing traditional methods. The engineered bacteria use outer-membrane vesicles as self-propelled delivery vehicles, targeting mucosal surfaces to provide mucosal immunity.
Researchers from Amsterdam UMC have made a breakthrough in developing an HIV vaccine with a germline-targeting strategy, inducing immune responses in participants. The phase one trial showed promising results, suggesting the potential for this approach to be further developed into a vaccine.
Researchers discovered 500 cryptic peptides found only in pancreatic tumors, which could be targeted by vaccines or engineered T cells to attack the cancer. The peptides were identified using immunopeptidomics and shown to slow down tumor growth in mice.
Researchers from Japan evaluate the LC16m8 vaccine, an attenuated vaccinia virus strain, for its efficacy and safety against mpox. The study confirms the vaccine's ability to induce strong immune responses and protect against mpox in mice, monkeys, and humans.
A novel vaccine platform uses genetically fused antigen to albumin, which is actively transported across the mucosal barrier by FcRn receptor. This results in protective systemic and mucosal antibody responses against SARS-CoV-2 and influenza A.
The review highlights the limitations of existing dengue vaccines, such as CYD-TDV and TAK-003, and the urgent need for more effective vaccines to protect millions of people. The Butantan-DV vaccine has shown promise with its single-dose regimen, but its efficacy against DENV-3 and DENV-4 is still unclear.
The BNT162b2 vaccine not only targets the COVID-19 virus but also helps reduce and control innate inflammation to other bacterial and fungal pathogens. By reprogramming innate immune cells, the vaccine reduces pro-inflammatory mediators, providing potential benefits beyond its primary target.
A mathematical modeling study suggests that sustained HIV remission or eradication could consistently reduce new HIV infections among men who have sex with men (MSM) in the Netherlands. However, transient remission with a risk of rebound may increase new infections if not closely monitored.
Researchers from the International Institute of Molecular and Cell Biology in Warsaw discovered a crucial role of enzyme TENT5A in extending poly(A) tails of therapeutic mRNA molecules, making them more stable and effective. Macrophages play a key role in vaccine effectiveness, capturing and neutralizing 'intruders' after administration.
A new vaccine platform developed at the University at Buffalo has demonstrated complete protection in mice against a deadly variant of bird flu. The vaccine, which combines key proteins hemagglutinin and neuraminidase, shows promise as a versatile and easy-to-produce vaccine that could be effective against evolving bird flu strains.
Cervical cancer cases worldwide reached 622,301 in 2022, with significant variations in age-standardized incidence rates across regions. Targeted prevention programs, especially HPV vaccination in low-income countries, are essential to reduce the global health burden.
The University of Virginia has appointed Dr. Mark T. Esser as the inaugural head of its Manning Institute, a $350 million facility aimed at transforming healthcare and accelerating new treatments. Esser brings decades of experience in developing new medical breakthroughs and will foster an ecosystem of innovation to attract biotechnolo...
A new study reveals that the US national vaccine strategy saved more money than it spent on testing, buying and delivering COVID-19 vaccines after just one year. The analysis found that the vaccines reduced serious illness and deaths, resulting in significant cost savings.
Researchers at HKU and CVVT create a nasal spray vaccine offering single-dose protection against H5N1 infection, inducing comprehensive immunity in the upper respiratory tract. The vaccine's high safety profile and ability to curb viral transmission make it a critical reserve for future outbreaks.
A promising new target for a Lyme disease vaccine has emerged: the Lyme bacterial protein CspZ. Genetic engineering revealed hidden regions that trigger a strong immune response. The modified protein promotes continuous production of protective antibodies, reducing the need for booster shots.
Researchers at the University of Maryland discovered a way to predict treatment success for cutaneous leishmaniasis, a devastating skin infection. By analyzing a patient's immune system, they identified a distinctive pattern that distinguishes responders from non-responders, with 90% accuracy.
The Vaccine Innovation Center at Korea University's College of Medicine successfully held the 2025 Vaccine Expert Training Program, attended by over 380 experts and researchers from various fields. The program aims to foster domestic vaccine R&D experts and promote the development of commercially available vaccines.
Researchers at MIT have developed a method to mass manufacture nanoparticles that target cancer cells, eliminating the need for manual polymer mixing and streamlining production. This approach integrates good manufacturing practice (GMP)-compliant processes, making it suitable for large-scale production of cancer treatments.
The MOPEVACLAS vaccine candidate is being tested in a Phase I clinical trial for its safety and immune response in humans. The vaccine targets Lassa fever, a hemorrhagic disease responsible for thousands of deaths worldwide each year.
The University of Texas at Arlington expert discusses the state's largest outbreak in 30 years, with fewer people getting vaccinated contributing to its spread. The MMR vaccine is 97% effective against measles and has been proven safe despite misconceptions about its safety.
Many teenagers enter adulthood with significant risk factors for cardiovascular disease, and emerging adulthood is a key time to address these risks. Interventions such as health practices, lifestyle changes, and improved access to healthcare can help reduce the risk of developing future cardiovascular disease.
A new reverse genetics system for African swine fever virus (ASFV) has been developed, enabling rapid vaccine development and research into the virus's biology. This technology can be adapted for other viruses, including lumpy skin disease, Zika, chikungunya, and Ebola viruses.
A growing body of evidence suggests a significant link between human papillomavirus (HPV) and heart disease. Researchers pooled data from nearly 250,000 patients in seven studies, finding HPV-positive individuals had a 40% higher likelihood of developing cardiovascular disease.
Researchers from La Jolla Institute for Immunology and UC San Diego discover Zika virus blocks dendritic cells' ability to alert T cells, while dengue virus stimulates pro-inflammatory cytokines, leading to a stronger but uncontrolled immune response. Understanding these differences is key to developing life-saving vaccines.
Researchers developed a universal vaccine that removes sugar molecules from coronavirus spike proteins, creating effective antibodies. The vaccine showed improved protection against various variants and potential applications for cancer treatment.
Researchers have made progress in understanding how Streptococcus pneumoniae constructs its capsule, a critical target for vaccine development. The study identified three categories of transporters that facilitate sugar building block transport, with relaxed specificity transporters posing potential risks to bacterial growth.
A TB vaccination has been shown to boost the immune system of bladder cancer patients, reducing cancer recurrence rates by up to 75% in a small pilot study. The vaccine was well-tolerated with no side effects and showed promising results in improving patient outcomes.
A study published in The Lancet Infectious Diseases found that a single dose of the Imvanex vaccine provides 84% protection against Mpox for HIV-negative individuals, but offers limited protection for those living with HIV. The study recommends that all at-risk groups, particularly those with HIV, receive two doses of the vaccine to ac...
A Phase 1 clinical trial is enrolling up to 55 healthy adults to test the safety and immunogenicity of a candidate Lassa vaccine. The trial aims to prevent Lassa fever, a viral hemorrhagic disease that can cause permanent hearing loss.
Researchers developed CeSPIACE, a 39-amino-acid peptide drug candidate that binds to the spike protein, blocking viral entry. It demonstrates strong binding to major SARS-CoV-2 variants and shows efficacy against multiple strains in vivo and in vitro experiments.
A study has established the importance of immunoglobulin A in generating a response to pneumonia vaccines. The research found that poor regulation of gut microbiota can lead to an inadequate immune response, leaving individuals vulnerable to respiratory infections.
A major clinical trial has identified ensitrelvir as an effective medication to prevent symptomatic COVID-19 in people exposed within households. The trial showed a 67% reduction in risk of illness among participants taking the antiviral compared to those given a placebo.
A recent study by Oregon Health & Science University and Weill Cornell Medicine has found that CMV lacking a certain viral protein complex can still be transmitted and cause significant harm to the developing fetus. The research suggests that additional vaccine targets need to be identified and explored to provide superior protection.
Researchers at the University of Leeds have developed a more affordable and lower-risk polio vaccine using virus-like particles (VLPs). VLPs mimic the outer protein shell of poliovirus but are empty inside, making them non-infectious yet capable of triggering an immune response.
The U.S. research ecosystem, fueled by high-performance computing, is facing a critical moment due to slow infrastructure growth and funding cuts. The National Science Foundation's staffing cuts will slow down the process of innovation, potentially harming the country's competitive edge in research.
A new study has discovered how antibodies help protect against Strep A infections and is contributing to the development of a Strep A vaccine. The research used the world's only human challenge model for Strep A, which uncovered the power and potential for this model to accelerate vaccine development.
A risk prediction model was developed to identify patients unlikely to complete HPV vaccination. The model uses patient demographics and clinical characteristics to guide targeted interventions, increasing vaccination rates among high-risk groups.
A new TB vaccine candidate has shown complete protection and a superior immune response in nonhuman primates compared to the existing BCG vaccine. The delta sigH vaccine resulted in a more balanced and effective elimination of the bacteria, with lower levels of inflammation and a different type of interferon triggered.
Researchers have identified powerful antibodies capable of neutralizing a wide range of norovirus strains, paving the way for designing a broadly effective norovirus vaccine. The discovery brings us closer to a vaccine that could provide lasting protection and prevent devastating effects of norovirus outbreaks.
Richard Willson, a University of Houston professor, has been elected Fellow of the Royal Society of Chemistry for his contributions to the chemical sciences. He has developed innovative methods to detect viruses and other biological threats using glow-in-the-dark nanoparticles.
Researchers developed a new vaccine platform that provides robust, long-lasting protection against multiple flu strains and COVID-19. The vaccine boasts 100% survival rates in vaccinated mice following challenge with either virus.
Lyme disease is a bacterial infection transmitted by ticks, posing an increasing threat in the U.S. Montana State University's Patrick Secor will study adaptations in Borrelia burgdorferi to illuminate how it circumvents its host's immune system. The goal is to discover new vaccine antigens and develop more effective treatments.
Researchers analyzed protein-coding RNA transcripts from single cells and lung fluid of infected pigs, monitoring immune cell alterations triggered by PRRSV strains of varying virulence. They found that high-virulence PRRSV caused severe lung damage and immune imbalance, while less virulent strains led to delayed lung damage with fewer...
A groundbreaking study published in eBioMedicine has shown that a new mRNA vaccine is effective in boosting immunity against tuberculosis. The vaccine demonstrated potent immune responses in infected mice and improved long-term protection when combined with the BCG vaccine.
A new biodegradable polymer-based delivery system efficiently transports mRNA, outperforming existing lipid nanoparticles in delivery efficiency and expression duration. The study also shows improved immune response results without liver accumulation or toxicity.